Effects of Curcumin-Piperine Supplementation in Fibromyalgia

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorAin Shams University

About this trial

The goal of this clinical trail is to evaluate the effectiveness and safety of curcumin-piperine supplementation in patients with fibromyalgia over 3 months compared to placebo.

Participants will:

Be randomly assigned to receive either curcumin and piperine supplements or a placebo.

Attend scheduled clinic visits for clinical assessments and blood sample collection.

Complete study questionnaires before and after treatment time frame.

The primary question the study aim to answer is:

Does Curcumin-piperine supplementation reduce pain intensity by Visual Analog Scale (VAS), compared with placebo?

The secondary questions this study aims to answer are:

Does supplementation improve fibromyalgia disease impact and quality of life? Does supplementation improve inflammatory biomarkers and oxidative stress? Does supplementation improve insulin resistance? Is curcumin and piperine supplementation safe and well tolerated?

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult women aged ≥18 years.

Patients with confirmed diagnosis of fibromyalgia, according to 2022 ACR Fibromyalgia criteria.

Disqualifiers

Diabetic patients (HbA1c ≥ 6.5).

Patients with chronic inflammatory or autoimmune diseases other than FM.

Patients allergic to curcumin or piperine.

Patients receiving other anti-inflammatory medications.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Curcumin - Piperine

    Dietary supplement

    The experimental group will receive Organic Nation Curcumin® oral coated tablets, administered once daily for 3 months, containing 1,200 mg of standardized curcumin (95% turmeric extract) combined with 10 mg of piperine (95% black pepper extract).

  • Placebo

    Other intervention

    the placebo group will receive matching oral placebo tablet containing inert excipients for the same duration. The placebo tablets will be identical in appearance, size, color, and packaging to the active supplement to maintain blinding.

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: Group A (Curcumin Group)Experimental treatment 1 intervention
Group B: Group B (Placebo Group)Placebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Assessment of pain severity measured by the Visual Analog Scale (VAS)

VAS is a self-administered instrument widely used in fibromyalgia research and clinical practice to assess pain intensity and monitor treatment response. The VAS uses a 10-cm horizontal line anchored by 0 (no pain) and 10 (worst imaginable pain). It will be measured at baseline, after 1 month, and after 3 months.

Time frame
3 months

Secondary outcomes

1

The Revised Fibromyalgia Impact Questionnaire (FIQR)

is a disease-specific, patient-reported outcome measure designed to assess disease severity and the overall impact of fibromyalgia. It comprises 21 items grouped into three domains: function (9 items assessing physical activities), overall impact (2 items evaluating the extent to which fibromyalgia interferes with goal achievement and causes a feeling of being overwhelmed), and symptoms (10 items assessing pain, fatigue, sleep quality, stiffness, depression, anxiety, memory, balance, tenderness, and environmental sensitivity). All items are rated on a 0-10 numeric scale. The total FIQR score ranges from 0 to 100, with higher scores indicating greater disease impact and symptom severity. It will be measured at baseline, after 1 month, and after 3 months

Time frame
3 months
2

The Hospital Anxiety and Depression Scale (HADS)

The scale consists of 14 self-reported items, divided equally into two domains: anxiety (HADS-A) and depression (HADS-D). Each item is rated on a 4-point Likert scale (0-3), yielding subscale scores ranging from 0 to 21, where higher scores indicate greater symptom severity. A cut-off score of ≥8 on either subscale is considered indicative of clinically relevant anxiety or depression. Elevated HADS scores in this population have been consistently associated with higher symptom severity, increased pain intensity, poorer sleep quality, reduced quality of life, and functional impairment. It will be measured at baseline, after 1 month, and after 3 months.

Time frame
3 months
3

The 36-Item Short Form Health Survey (SF-36)

SF-36 is a validated, self-administered, generic instrument used to assess health-related quality of life in fibromyalgia research by evaluating both physical and mental health status. It consists of 36 items covering eight domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Domain scores are transformed to a scale ranging from 0 to 100, where 0 represents the worst and 100 the best perceived health status, and are aggregated into two summary measures: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). It will be measured at baseline, after 1 month, and after 3 months

Time frame
3 months
4

Serum inflammatory biomarkers: IL-6

Collected serum samples will be stored at -80 C until analysis. Serum IL-6 will be assessed using enzyme-linked immunosorbent assay (ELISA) kits. It will be measured at the start and end of the study (after 3 months).

Time frame
3 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Ain Shams University

Lead sponsor

Sinai University

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: